Search This Blog

Wednesday, May 20, 2026

Roivant fiscal Q4 profit from continuing operations on $770.2M gain; $2.25B Moderna settlement

 

Roivant swings to $355.7M fiscal Q4 profit from continuing operations on $770.2M gain, discloses $2.25B Moderna settlement

  • On its Q4 2025 earnings call, Roivant updated investors on the 1,402 program’s efficacy profile.
  • The 1,402 study reported 73% ACR20 response rates, with over half of patients achieving ACR50.
Posted by at

No comments:

Post a Comment

Note: Only a member of this blog may post a comment.

Subscribe to: Post Comments (Atom)